DEFA14A: Apogee Therapeutics Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote

Apogee Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, with voting open until June 16, 2025, covering director elections, auditor ratification, and executive compensation advisory vote frequency.

Summary

• Apogee Therapeutics, Inc. will hold its Annual Meeting of Stockholders on June 17, 2025, at 11:00 AM ET, conducted virtually.
• Stockholders can access proxy materials online or request a free copy by June 3, 2025.
• Voting is open until June 16, 2025, at 11:59 PM ET.
• The meeting will address the election of three Class II Directors (Lisa Bollinger, Tomas Kiselak, and Nimish Shah) for terms expiring in 2028.
• Stockholders will also vote on ratifying the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending December 31, 2025.
• An advisory vote on the frequency (1 year) of future votes to approve named executive officer compensation is also scheduled.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral to slightly positive sentiment as it reflects routine corporate governance activities.

Positives

• The virtual format of the annual meeting enhances accessibility for stockholders.
• Stockholders have multiple options to access proxy materials and cast their votes.
• The agenda includes standard corporate governance matters such as director elections and auditor ratification.

Future Outlook

The document outlines the standard procedures for an annual meeting, focusing on governance and shareholder voting rights.

Industry Context

This announcement is typical for publicly traded companies, ensuring compliance with SEC regulations and providing shareholders the opportunity to participate in corporate governance.

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction through voting.
• The outcome of the votes will impact the composition of the board of directors and the selection of the company's auditor.

Next Steps

• Stockholders should review the proxy materials and cast their votes by the deadline.
• The company will proceed with the Annual Meeting on June 17, 2025.
• The company will implement the outcomes of the votes, including the election of directors and ratification of the auditor.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Director Election, Auditor Ratification, Executive Compensation, Apogee Therapeutics